Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 554, Issue 1-2, 2004, Pages 139-148

  Blasiak, Janusz ^a   Arabski, Michal ^a   Krupa, Renata ^a   Wozniak, Katarzyna ^a   Rykala, Jan ^b   Kolacinska, Agnieszka ^b   Morawiec, Zbigniew ^b   Drzewoski, Jozef ^c   Zadrozny, Marek ^d  

^a UNIVERSITY OF LODZ   (Poland)

^b N Copernicus Hospital   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Breast cancer; Comet assay; DNA damage; DNA repair; Doxorubicin

Indexed keywords

3 METHYLADENINE DEOXYRIBONUCLEIC ACID GLYCOSYLASE II; DNA BASE; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; DNA GLYCOSYLTRANSFERASE; DOXORUBICIN; ENDONUCLEASE; HYDROGEN PEROXIDE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ALKYLATION; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MUTAGENESIS; OXIDATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

ALKYLATING AGENTS; BREAST NEOPLASMS; DNA DAMAGE; DNA REPAIR; HUMANS; MUTAGENS; OXIDATIVE STRESS;

EID: 4344627438     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2004.04.001     Document Type: Article

References (44)

1. Scully R., Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 408:2000;429-432
2. Wright C.L., Stewart I.D. Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am. J. Surg. Pathol. 27:2003;1393-1406
3. Bohr V.A., Evans M.K., Fornace A.J. Biology of the disease: DNA repair and its pathogenic implications. Lab. Invest. 61:1986;143-161
4. Vendrik C.P.J., Bergers J.J., De Jong W.H., Steerenberg P.A. Resistance to cytostatic drugs at the cellular level. Cancer Chemother. Pharmacol. 29:1992;413-429
5. Rajaee-Behrabani N., Schmezer P., Risch A., Rittgen W., Kayser K.W., Dienemann H., Schultz V., Drings P., Thiel S., Bartsch H. Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int. J. Cancer. 95:2001;86-91
6. J. Higginson, C.S. Muir, N. Munoz, Cambridge Monographs on Cancer Research: Human Cancer: Epidemiology and Environmental Causes, Cambridge University Press, Cambridge, 1992, pp. 377-387.
7. Tokunaga M., Land C.E., Yamamoto T., Asano M., Tokuoka S., Ezaki H., Nishimori J. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat. Res. 112:1987;243-272
8. Ziegler R.G., Hoover R.N., Pike M.C., Hildesheim A., Nomura A.M., West D.W., Wu-Williams A.H., Kolonel L.N., Horn-Ross P.L., Rosenthal J.F., Hyer M.B. Migration patterns and breast cancer risk in Asian-American women. J. Natl. Cancer Inst. 85:1993;1819-1827
9. Grover P.L., Martin F.L. The initiation of breast cancer. Carcinogenesis. 23:2002;1095-1102
10. Kute T.E., Grondahl-Hansen J., Shao S.M., Long R., Russel G., Brünner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res. Treat. 47:1998;9-16
11. Rossi C.R., Mocellin S., Pilati P., Foletto M., Quintieri L., Palatini P., Lise M. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg. Oncol. Clin. N. Am. 12:2003;781-794
12. Quiles J.L., Huertas J.R., Battino M., Mataix J., Ramirez-Tortosa M.C. Antioxidant nutrients and adriamycin toxicity. Toxicology. 180:2002;79-95
13. Collins A.R., Duthie S.J., Dobson V.L. Direct enzymatic detection of endogenous base damage in human lymphocyte DNA. Carcinogenesis. 14:1993;1733-1735
14. David-Cordonnier M.-H., Laval J., O'Neill P. Clustered DNA damage, influence on damage excision by XRS5 nuclear extracts and Escherichia coli Nth and Fpg proteins. J. Biol. Chem. 275:2000;11865-11873
15. Boiteux S., Gajewski E., Laval J., Dizdaroglu M. Substrate specificity of the Escherichia coli Fpg protein (formamidopyrimidine-DNA glycosylase): excision of purine lesions in DNA produced by ionizing radiation or photosensitization. Biochemistry. 31:1992;106-110
16. Tchou J., Kasai H., Shibutani S., Chung M.H., Laval J., Grollman A.P., Nishimura S. 8-Oxoguanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc. Natl. Acad. Sci. USA. 88:1991;4690-4694
17. Laval J. Two enzymes are required for strand incision in repair of alkylated DNA. Nature. 269:1977;829-832
18. Tudek B., VanZeeland A.A., Kusmierek J.T., Laval J. Activity of Escherichia coli DNA-glycosylases on DNA damaged by methylating and ethylating agents and influence of 3-substituted adenine derivatives. Mutat. Res. 407:1998;169-176
19. Singh N.P., McCoy T., Tice R.R., Schneider E.L. A simple technique for of low levels of DNA damage in individual cells. Exp. Cell Res. 175:1988;184-192
20. Klaude M., Eriksson S., Nygren J., Ahnstrom G. The comet assay: mechanisms and technical considerations. Mutat. Res. 12:1996;89-96
21. Blasiak J., Gloc E., Woźniak K., Drzewoski J., Zadrozny M., Skorski T., Pertynski T. Free radicals scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells. Mutat. Res. 535:2003;25-34
22. Ashby J., Tinwell H., Lefevre P.A., Browne M.A. The single cell gel electrophoresis assay for induced DNA damage (comet assay): measurement of tail length and moment. Mutagenesis. 10:1995;85-90
23. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35:2000;206-221
24. Harrouk W., Codrington A., Vinson R., Robaire B., Hales B.F. Paternal exposure to cyclophosphamide induces DNA damage and alters the expression of DNA repair genes in the rat preimplantation embryo. Mutat. Res. 46:2000;229-241
25. Chow M., Koo J., Ng P., Rubin H. Random population-wide genetic damage induced in replicating cells treated with methothrexate. Mutat. Res. 413:1998;251-264
26. Backus H.H., Pinedo H.M., Wouters D., Kuiper C.M., Jansen G., van Groeningen C.J., Peters G.J. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol. Res. 12:2000;231-239
27. Blasiak J., Widera K., Pertynski T. Hyperthermia can differentially modulated the repair of doxorubicin-damaged DNA in normal and cancer cells. Acta Biochim. Polon. 50:2003;249-253
28. Slupianek A., Hoser G., Majsterek I., Bronisz A., Malecki M., Blasiak J., Fishel R., Skorski T. Fusion tyrosine kinases induce therapeutic drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase and protection from apoptosis. Mol. Cell. Biol. 22:2002;4189-4201
29. Blasiak J., Gloc E., Pertynski T., Drzewoski J. DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine. Anti-Cancer Drugs. 13:2002;1055-1060
30. Blasiak J., Gloc E., Mlynarski W., Drzewoski J., Skorski T. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leukemia Res. 26:2002;1093-1096
31. de Almodovar J.M.R., Guirado D., Nunez M.I., Lopez E., Guerrero R., Valenzuela M.T., Villalobos M., del Moral R. Individualisation of radiotherapy in breast cancer patients: possible usefulness of a DNA damage assay to measure normal cell radiosensitivity. Radiother. Oncol. 62:2002;327-333
32. Müller-Vogt U.S., Maurer J.E.E., Grabenbauer G.G., Distel L.V.R., Iro H., Steinhart H. Altered DANN repair capacity in young patients suffering from multiple cancers. Int. J. Mol. Med. 11:2003;669-674
33. Wei Q., Cheng L., Hong W.K., Spitz M.R. Reduced DNA repair capacity in lung cancer patients. Cancer Res. 56:1996;4103-4107
34. Hsu T.C. Genetic predisposition to cancer with special reference to mutagen sensitivity. In Vitro Cell. Dev. Biol. 23:1987;591-603
35. Hsiu T.C., Spitz M.R., Schantz S.P. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 1:1991;83-89
36. Rajaee-Behbahani N., Schmezer P., Risch A., Rittgen W., Keiser K.W., Dienemann H., Schulz V., Drings P., Thiel S., Bartsch H. Altered DANN repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int. J. Cancer. 95:2001;86-91
37. Schmezer P., Rajaee-Behbahani N., Risch A., Thiel S., Rittgen W., Drings P., Dienemann H., Kayser K.W., Schultz V., Bartsch H. Rapid screening assay for mutagen sensitivity and DANN repair capacity in human peripheral blood lymphocytes. Mutagenesis. 16:2001;25-30
38. Sturgis E.M., Wie Q. Genetic susceptibility-molecular epidemiology of head and neck cancer. Curr. Opin. Oncol. 14:2002;307-310
39. Berwick M., Vineis P. Markers of DNA repair and susceptibility to cancer in human: an epidemiological review. J. Nat. Cancer Inst. 92:2000;874-897
40. Jaloszynski P., Kujawski M., Czub-Swierczek M., Markowska J., Szyfter K. Bleomycin-induced DNA damage and its removal in lymphocytes of breast cancer patients studied by comet assay. Mutat. Res. 385:1997;223-233
41. Parshad R., Price F.M., Bohr V.A., Cowans K.H., Zujewski J.A., Stanford A.A. Deficient DNA repair capacity, a predisposing factor in breast cancer. Brit. J. Cancer. 74:1996;1-5
42. Scott D., Barber J.B.P., Levine E.L., Burrill W., Roberts S.A. Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: a test for predisposition? Brit. J. Cancer. 77:1998;614-620
43. Helzlsouer K.J., Harris E.I., Parshad R., Fogel S., Bigbee W.L., Sanford K.K. Familial clustering of breast cancer: possible interaction between DNA repair proficiency and radiation exposure in the development of breast cancer. Int. J. Cancer. 64:1995;14-17
44. Helzlsouer K.J., Harris E.I., Parshad R., Perry H.R., Price F.M., Sanford K.K. DNA repair proficiency: potential susceptibility factor for breast cancer. J. Natl. Cancer Inst. 88:1996;754-755